Vivian G. Oehler

Nov 21, 2024 | jamanetwork.com | Elias Jabbour |Vivian G. Oehler |Paul Koller

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial Podcast (18:46) 0:00 / 0:00 Key Points Question What is the pharmacokinetic profile of olverembatinib, which is approved in China, in non-Chinese individuals, and is it a safe and efficacious treatment option for patients with relapsed/refractory chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia, including those previously...